

Scientific Committee on Consumer Safety (SCCS) WG on Methodologies

Venue: Luxembourg

Meeting date: 01 July 2015

Minutes

1. WELCOME AND APOLOGIES

The Chair welcomed the participants, in particular a representative from the Scientific Committee on Health and Environmental Risks (SCHER), three AD-HOC experts, as well as three observers from cosmetic industry. There were three apologies.

2. ADOPTION OF THE AGENDA

The agenda was adopted as presented.

3. DECLARATION OF INTEREST ON MATTERS ON THE AGENDA

The Chair requested participants to declare any conflict of interest regarding matters on the agenda. None of the participants declared any conflict of interest.

4. RE-ASSESSMENT OF GRADING OF SENSITIZATION POTENCY -> A.M. SESSION

Welcome and scope of the meeting: the Chair made an introduction and explained that the current grading systems of sensitization potency were established around a decade ago and that scientific knowledge may have changed since then in a way that a reassessment is required.

Three presentations followed:

• Potency classification of skin sensitizers (suggestions from the Technical Committee of classification and labelling, published in Contact Dermatitis 2005) by Carola Lidén. Her presentation gave an overview on grading systems and concluded that the grading system of sensitization potency taken in the SCCP Memorandum (2005) is up to date and was recently implemented in GHS and CLP. She stressed that human data on elicitation is very important for prevention

of clinical diseases and that animal data will be important for risk assessment in the future as well.



• Suggested updates and new data concerning potency classification (animal/human data) by David Basketter. His presentation dealt with methodological issues of identifying and predicting sensitisation and compared animal and human data. He proposed up to six potency categories of sensitisers only based on human data. Finally he concluded that it is too premature to start using *in-vitro* methods to predict potency.



• Use of in-vitro data for potency classification by Jean-Pierre Lepoittevin. His presentation reviewed various advantages but also limitations of the *in vitro* approach and concluded that potency prediction of sensitisation is still a long-term objective and much effort is put now in how to combine the results of *in silico*, *in chemico* and *in vitro* tests.



A general discussion took place. The group will submit the proposal to the SCCS Plenary for drafting an update of the earlier Memorandum that also considers human data.

5. Internal meeting of the WG Methodologies -> P.M session

SCCS Notes of Guidance – 9th revision - changes and update: contributions received were discussed/modified. Further work is still needed before finalising the whole document (next WG meeting planned on 09/09). It is planned to be added on the agenda of the September Plenary meeting (29/09).

6. ANY OTHER BUSINESS

Next meetings are planned on 9 September (4 November 2015 to be confirmed).

Attendance list of external experts:

SCHER: Dr Renate Krätke

<u>Industry:</u> representatives of Cosmetics Europe: **Dr Dagmar Bury** from L'OREAL Research & Innovation, **Dr Petra Kern** from P&G and **Ms Martina Klaric** from Cosmetics Europe.

<u>AD-HOC experts</u>: **Prof. Carola Lidén** from Karolinska Institutet, Institute of Environmental Medicine in Stockholm - SE, **Dr David Basketter** from DABMEB Consultancy Ltd from Sharnbrook - UK, and **Prof. Jean-Pierre Lepoittevin** from Laboratoire de Dermatochimie, ILB, in Strasbourg – FR.